CD274 and adenocarcinoma: Additionally, in two randomized, first-line phase III trials conducted in China (Orient-155 and Orient-166), the combination of sintilimab (anti-PD-1) plus chemotherapy demonstrated significant survival benefits compared with chemotherapy alone in metastatic/advanced patients with oesophageal squamous cell carcinoma (Orient-15, PD-L1 CPS ≥10, 17.2 months versus 13.6 months; P = 0.0018 and all patients, 16.7 months versus 12.5 months; P < 0.0001) and adenocarcinoma (Orient-16, PD-L1 CPS ≥5, 18.4 months versus 12.9 months; P = 0.0023 and all patients, 15.2 months versus 12.3 months; P = 0.009).